EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Proof-of-concept development of a cost-effective PACE-based assay for CYP2C19 genotyping

Chonticha Sirikul, Auttachai Saejia, Nampeung Anukul

Journal of Associated Medical Sciences · 13.07.2026 · 59 (3) · 238-246

DOI: 10.66285/jams.2025.097 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Associated Medical Sciences, online erschienen am 13.07.2026. Verfasst von Chonticha Sirikul und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pharmacogenomic testing of the CYP2C19 gene is a fundamental component of precision medicine, enabling personalized dose adjustments for critical medications, including antiplatelet agents and antidepressants. However, the high cost of currently available commercial genotyping kits creates a financial burden that limits patient accessibility to these essential tests.

Objectives

This study aimed to preliminarily develop and analytically evaluate a novel PCR Allelic Competitive Extension (PACE) assay for genotyping CYP2C19*2, *3, and *17. Materials and methods: Thirty DNA samples extracted from buffy coat were analyzed using specifically designed allele-specific primers for CYP2C19*2, *3, and *17. The genotyping results were reported as zygosity status and evaluated for concordance with the TaqManTM Drug Metabolism Genotyping Assay.

Results

The analysis identified *1/*1 (53.3%), *1/*2 (30.0%), *1/*3 (10.0%), and *2/*2 (6.7%) genotypes, while the allele frequencies were 73.3% for *1, 21.7% for *2, 5.0% for *3, and 0% for *17. The results from the PACE technique demonstrated 100% concordance with those obtained from the commercial TaqManTM assay and produced clear, well-separated data points in the allelic discrimination plot analysis.

Conclusion

The novel PACE technique provides high accuracy, equivalent to commercially available test kits, while offering a more cost-effective approach, with a reagent cost of only USD 4.34 (135 Thai baht) per sample for CYP2C19*2, *3, and *17 genotyping. It represents an alternative to CYP2C19 genotyping, supporting the advancement of personalized medicine and reducing the longterm financial burden on healthcare.

Zitieren

APA

Sirikul, C., Saejia, A., & Anukul, N. (2026). Proof-of-concept development of a cost-effective PACE-based assay for CYP2C19 genotyping. Journal of Associated Medical Sciences, 59(3), 238-246. https://doi.org/10.66285/jams.2025.097

Vancouver

Sirikul C, Saejia A, Anukul N. Proof-of-concept development of a cost-effective PACE-based assay for CYP2C19 genotyping. Journal of Associated Medical Sciences. 2026;59(3):238-246. doi:10.66285/jams.2025.097

BibTeX
@article{Sirikul2026,
  author = {Sirikul, Chonticha and Saejia, Auttachai and Anukul, Nampeung},
  title = {Proof-of-concept development of a cost-effective PACE-based assay for CYP2C19 genotyping},
  journal = {Journal of Associated Medical Sciences},
  year = {2026},
  volume = {59},
  number = {3},
  pages = {238--246},
  doi = {10.66285/jams.2025.097}
}
Kostenlos starten →